BNP Paribas Financial Markets
CMMB

BNP Paribas Financial Markets’s Chemomab Therapeutics CMMB Stock Holding History

BNP Paribas Financial Markets’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11K Sell
6,805
-1,620
-19% -$2.73K ﹤0.01% 5366
2026
Q1 		$13.2K Buy
8,425
+300
+4% +$513 ﹤0.01% 5168
2025
Q4 		$13.4K Buy
8,125
+2,375
+41% +$6.3K ﹤0.01% 5108
2025
Q3 		$15.1K Buy
5,750
+2,275
+65% +$8.39K ﹤0.01% 4948
2025
Q2 		$16.1K Buy
3,475
+850
+32% +$4.21K ﹤0.01% 4694
2025
Q1 		$11.4K Buy
2,625
+1,000
+62% +$7.01K ﹤0.01% 4687
2024
Q4 		$11.8K Buy
+1,625
New +$10.3K ﹤0.01% 4825

Other funds holding CMMB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $161M AUM
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets's CMMB Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Chemomab Therapeutics (CMMB) stake by 19% in Q2 2026, selling an estimated $2.73K and leaving 6,805 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #5366.

BNP Paribas Financial Markets first reported a position in CMMB in Q4 2024 and has held it in 7 quarters since. The position peaked at $16.1K in Q2 2025. 13 funds tracked by Wall St. Rank hold CMMB as of Q2 2026.

  • BNP Paribas Financial Markets held 6,805 shares of Chemomab Therapeutics worth $11K as of Q2 2026.
  • BNP Paribas Financial Markets sold 1,620 Chemomab Therapeutics shares in Q2 2026, an estimated $2.73K.
  • Chemomab Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5366 holding.
  • BNP Paribas Financial Markets first reported a position in Chemomab Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Chemomab Therapeutics position peaked at $16.1K in Q2 2025.
  • 13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.